Alumis (ALMS) files for proposed IPO

Alumis (NASDAQ: ALMS) has filed for a proposed IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024."

Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities will serve as underwriters.​

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• Cosa Resources announces C$5 million bought deal private placement
• 3 E Network Technology (MASK) files for 17.13M share offering by selling stockholders